Losartan Potassium
Product Images NDC 42571-112

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 42571-112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Micro Labs Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartanpotassium 100mg

Losartan Potassium Tablets, USP 100 mg tablet label manufactured by Micro Labs Limited. The label states storage conditions at 25°C with permitted excursions, contains 30 tablets, and is marked Rx Only. It includes barcode and pharmacist dispensing instructions with Patient Information Leaflet. Manufactured for Micro Labs USA, Inc., Somerset, NJ.*

FDA Label Image

Losartanpotassium 25mg

Label of LOSARTAN POTASSIUM Tablets, USP 25 mg by Micro Labs Limited, showing a 30-tablet count. The label includes storage instructions (store at 25°C with permitted excursions), a pharmacist note to dispense with patient information leaflet, and details of manufacturing in India for Micro Labs USA, Inc.*

FDA Label Image

Losartanpotassium 50mg

Losartan Potassium Tablets USP 50 mg packaging label showing a 30 tablet count. Manufactured by Micro Labs Limited in India and for Micro Labs USA, Inc. The label includes storage instructions, NDC 42571-111-30, and a request for pharmacists to dispense with the Patient Information Leaflet.*

FDA Label Image

Losartanpotassium Figa

A line graph comparing the percentage of patients with a primary endpoint over study months for Atenolol (dotted line) and Losartan Potassium (solid line). The x-axis represents study months up to 66 months, and the y-axis shows the percentage of patients. The graph includes a note on adjusted risk reduction of 13% with p=0.021.*

FDA Label Image

Losartanpotassium Figb

A line graph comparing the percentage of patients experiencing fatal or non-fatal stroke over study months for Atenolol and Losartan Potassium. The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients. Atenolol is represented by a dotted line, Losartan Potassium by a solid line, with Losartan showing a lower percentage over time. Text on the chart notes an adjusted risk reduction of 25% with p=0.001.*

FDA Label Image

Losartanpotassium Figc

A forest plot chart comparing hazard ratios with 95% confidence intervals for Losartan Potassium versus Atenolol across multiple patient subgroups including overall results, age, gender, race, ischemic heart disease (ISH), diabetes, and history of cardiovascular disease (CVD). The chart shows event rates and favors either Losartan Potassium or Atenolol for primary composite outcomes and stroke (fatal/non-fatal). Sample size proportions are indicated by symbol size.*

FDA Label Image

Losartanpotassium Figd

A line chart comparing the percentage of patients with events over a 48-month period for Losartan Potassium versus placebo. The solid line represents Losartan Potassium, and the dashed line represents placebo, showing a risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

Losartanpotassium Stru

Chemical structure of losartan potassium, depicting its molecular composition including a biphenyl tetrazole group and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.